United States HR 7848: Right Drug Dose Now Act of 2024

Bill Text

I 
118THCONGRESS 
2
DSESSION 
H. R. 7848 
To  update  the  National  Action  Plan  for  Adverse  Drug  Event  Prevention  
to  consider  advances  in  pharmacogenomic  research  and  testing,  to  im-
prove  electronic  health  records  for  pharmacogenomic  information,  and  
for other purposes. 
IN  THE  HOUSE  OF  REPRESENTATIVES  
MARCH29, 2024 
Mr. S
WALWELL(for himself and Mr. CRENSHAW) introduced the following 
bill; which was referred to the Committee on Energy and Commerce 
A  BILL  
To  update  the  National  Action  Plan  for  Adverse  Drug  Event  
Prevention  to  consider  advances  in  pharmacogenomic  re-
search  and  testing,  to  improve  electronic  health  records  
for  pharmacogenomic  information,  and  for  other  pur-
poses. 
Be  it  enacted  by  the  Senate  and  House  of  Representa-1
tives of the United States of America in Congress assembled, 2
SECTION 1. SHORT TITLE. 3
This Act may be cited as the ‘‘Right Drug Dose Now 4
Act of 2024’’. 5
SEC. 2. TABLE OF CONTENTS. 6
The table of contents of this Act is as follows: 7
VerDate Sep 11 2014     04:08 Apr 13, 2024    Jkt 049200    PO 00000    Frm 00001    Fmt 6652    Sfmt 6201    E:\BILLS\H7848.IH    H7848
kjohnson on DSK7ZCZBW3PROD with $$_JOB

2 
•HR  7848  IH
Sec.  1.  Short title. 
Sec.  2.  Table of contents. 
Sec.  3.  National Action Plan for Adverse Drug Event Prevention. 
Sec.  4.  Adverse  drug  event  and  pharmacogenomic  testing  education  for  health  
care professionals. 
Sec.  5.  Improving  EHR  systems  to  improve  the  use  of  pharmacogenomic  infor-
mation. 
SEC.   3.   NATIONAL   ACTION   PLAN   FOR   ADVERSE   DRUG   1
EVENT PREVENTION. 2
The Secretary of Health and Human Services (in this 3
Act referred to as the ‘‘Secretary’’) shall— 4
(1)  not  later  than  180  days  after  the  date  of  5
enactment   of   this   Act,   in   coordination   with   the   6
heads  of  other  relevant  Federal  departments  and  7
agencies,  submit  a  report  to  the  Congress  on  the  im-8
plementation  of  the  National  Action  Plan  for  Ad-9
verse  Drug  Event  Prevention  of  the  Department  of  10
Health   and   Human   Services,   including   on   the   11
progress in meeting the target outcomes approved by 12
the  Federal  Interagency  Steering  Committee  for  Ad-13
verse Drug Events; 14
(2)  convene  the  Federal  Interagency  Steering  15
Committee  for  Adverse  Drug  Events  to  update  the  16
National  Action  Plan  for  Adverse  Drug  Event  Pre-17
vention; and 18
(3)  require  such  Committee,  in  updating  the  19
National  Action  Plan  for  Adverse  Drug  Event  Pre-20
vention— 21
VerDate Sep 11 2014     04:08 Apr 13, 2024    Jkt 049200    PO 00000    Frm 00002    Fmt 6652    Sfmt 6201    E:\BILLS\H7848.IH    H7848
kjohnson on DSK7ZCZBW3PROD with $$_JOB

3 
•HR  7848  IH
(A)  to  consider  advances  in  scientific  un-1
derstanding  and  technology  pertaining  to  drug-  2
gene  interactions  (including  interactions  among  3
multiple  drugs  and  genes),  clinical  outcomes,  4
health  care  utilization,  and  the  decreasing  cost  5
of genetic testing; 6
(B)  to  assess  the  role  of  pharmacogenetics  7
testing  combined  with  clinical  decision  support  8
as an evidence-based prevention tool; and 9
(C)   to   evaluate   operating   characteristics   10
for  Federal  adverse  drug  event  monitoring  sys-11
tems  and  expand  capabilities  to  identify  genetic  12
associations in adverse events. 13
SEC.  4.  ADVERSE  DRUG  EVENT  AND  PHARMACOGENOMIC  14
TESTING    EDUCATION    FOR    HEALTH    CARE    15
PROFESSIONALS. 16
The  Secretary  shall  issue  guidance  for  health  care  17
providers  and  health  care  leaders,  including  administra-18
tors,  primary  and  specialty  care  physicians,  pharmacists,  19
nurse  practitioners,  physician  assistants,  physician  med-20
ical   geneticists,   laboratory   medical   geneticists,   genetic   21
counselors,  medical  educators,  and  the  faculty  of  schools  22
of medicine and other schools of health professions, on the 23
following: 24
VerDate Sep 11 2014     04:08 Apr 13, 2024    Jkt 049200    PO 00000    Frm 00003    Fmt 6652    Sfmt 6201    E:\BILLS\H7848.IH    H7848
kjohnson on DSK7ZCZBW3PROD with $$_JOB

4 
•HR  7848  IH
(1)  Pharmacogenomic  testing  and  the  extent  of  1
its ability to prevent adverse drug reactions. 2
(2)  Pharmacogenomic  testing,  drug  interaction  3
alerting  systems,  when  to  refer  to  or  consult  with  a  4
genetics  provider,  and  the  applicable  Federal  stand-5
ards of care for patients who are suspected or known 6
to  have  a  genetic  variant  that  is  known  to  impact  7
drug metabolism or adverse reactions. 8
(3)  Evidence-based  information  that  would  en-9
courage   individuals   and   their   health   care   profes-10
sionals  to  consider  pharmacogenomic  testing  as  part  11
of  their  health  care  plan  to  the  extent  appropriate.  12
(4)  The  role  of  medical  professio